GSK has reported promising results with a drug to treat the severe itching that plagues patients with rare cholestatic liver disease primary biliary cholangitis (PBC). Interim results from the ...

and primary biliary cirrhosis (PBC). CD and PBC are two autoimmune disorders whose association has been widely established (mean prevalence of CD in PBC and PBC in CD is 3.1 and 0.36%, respectively).

The prognosis and natural history of primary biliary cirrhosis (PBC) have improved significantly during the last few decades. Patients are diagnosed at earlier stages, are more likely to be ...

Researchers identify various factors that correlate with outcomes in patients with primary biliary cholangitis. Primary biliary cholangitis (PBC) is a rare disorder that often leads to cirrhosis and ...

Or dealing with constant itching that won’t go away, no matter what lotion you try. These might seem like minor inconveniences, but for people with primary biliary cholangitis (PBC), formerly known as ...

Objective Hepatocellular carcinoma (HCC) is an infrequent yet critical event in primary biliary cirrhosis (PBC); however, predictive tools remain ill-defined. Our objective was to identify candidate ...

Interferon-gamma levels could discriminate between patients with PBC who respond to ursodeoxycholic acid treatment and those who do not independently of cirrhosis. The levels of interferon-gamma ...

September is the perfect time to turn up the volume on conversations about Primary Biliary Cholangitis (PBC) and the symptoms people living with it experience, in support of PBC Awareness Month.

Saroglitazar is under clinical development by Zydus Therapeutics and currently in Phase III for Primary Biliary Cholangitis (Primary Biliary Cirrhosis). According to GlobalData, Phase III drugs for ...

Mrs K Cauch-Dudek, Toronto Hospital, Western Division, 399 Bathurst St, West Wing 4–833, Toronto, Ontario M5T 2S8, Canada. Background—Fatigue is a frequent and debilitating symptom in patients with ...

The diagnostic value of primary biliary cholangitis (PBC)-specific antibodies in patients with elevated alkaline phosphatase (ALP) and gamma-glutamyl transferase (GGT) levels, and other ...

The FDA has granted Cour Pharmaceuticals orphan drug designation for CNP-104, a biodegradable nanoparticle in development for the treatment of primary biliary cholangitis, the company announced in ...